RecruitingNCT07156149
Fabhalta Capsules Specified Drug-use Survey
Fabhalta Capsules Specified Drug-use Survey(C3 Glomerulopathy, CLNP023B11401)
Sponsor
Novartis Pharmaceuticals
Enrollment
50 participants
Start Date
Sep 17, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
The objective of this study is to evaluate the safety and effectiveness of Fabhalta in patients with C3 glomerulopathy in clinical practice.
Eligibility
Min Age: 0 YearsMax Age: 100 Years
Inclusion Criteria1
- All patients who have used Fabhalta for C3 glomerulopathy (including patients with recurrent C3 glomerulopathy post renal transplant).
Exclusion Criteria1
- Use of iptacopan for an indication not yet approved under the Clinical Trials Act or GCP (e.g., patient-requested medical treatment, investigator-initiated clinical trial)
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(26)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07156149
Related Trials
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
NCT0395544550 locations
Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN
NCT062097366 locations
Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy
NCT041831014 locations
Home Reported Outcomes in C3G Study
NCT070295421 location
National Registry of Rare Kidney Diseases
NCT060658521 location